- Home
- CHN vs GUTS Comparison
CHN vs GUTS Comparison
Compare CHN & GUTS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CHN
- GUTS
- Stock Information
- Founded
- CHN 1992
- GUTS 2010
- Country
- CHN United States
- GUTS United States
- Employees
- CHN N/A
- GUTS N/A
- Industry
- CHN Investment Managers
- GUTS
- Sector
- CHN Finance
- GUTS
- Exchange
- CHN Nasdaq
- GUTS NYSE
- Market Cap
- CHN 114.9M
- GUTS 110.1M
- IPO Year
- CHN N/A
- GUTS 2024
- Fundamental
- Price
- CHN $12.19
- GUTS $2.02
- Analyst Decision
- CHN
- GUTS Buy
- Analyst Count
- CHN 0
- GUTS 2
- Target Price
- CHN N/A
- GUTS $18.00
- AVG Volume (30 Days)
- CHN 31.8K
- GUTS 275.0K
- Earning Date
- CHN 01-01-0001
- GUTS 02-02-2025
- Dividend Yield
- CHN 0.19%
- GUTS N/A
- EPS Growth
- CHN N/A
- GUTS N/A
- EPS
- CHN N/A
- GUTS N/A
- Revenue
- CHN N/A
- GUTS $97,000.00
- Revenue This Year
- CHN N/A
- GUTS N/A
- Revenue Next Year
- CHN N/A
- GUTS N/A
- P/E Ratio
- CHN N/A
- GUTS N/A
- Revenue Growth
- CHN N/A
- GUTS N/A
- 52 Week Low
- CHN $9.00
- GUTS $1.74
- 52 Week High
- CHN $12.98
- GUTS $14.50
- Technical
- Relative Strength Index (RSI)
- CHN 50.22
- GUTS 41.72
- Support Level
- CHN $12.41
- GUTS $2.00
- Resistance Level
- CHN $12.58
- GUTS $2.58
- Average True Range (ATR)
- CHN 0.29
- GUTS 0.20
- MACD
- CHN 0.03
- GUTS -0.02
- Stochastic Oscillator
- CHN 41.81
- GUTS 3.61
About CHN China Fund Inc. (The)
CHINA FUND INC is a non-diversified, closed-end management investment company. Its investment objective is a long-term capital appreciation which it seeks to achieve by investing in equity securities with trading in China and outside China. It invests in various industries such as Insurance, Entertainment, Machinery, Electrical Equipment, Beverages, Hotels, Restaurants and Leisure among others.
About GUTS FRACTYL HEALTH INC
Fractyl Health Inc is a metabolic therapeutics company focused on pioneering new approaches to the treatment of metabolic diseases, including type 2 diabetes and obesity. The company focuses on transforming metabolic disease treatment from chronic symptomatic management to durable disease modifying therapies that target the organ level root causes of T2D and obesity.